Wire · operational-macro
Werewolf Therapeutics And Ambros Therapeutics Merge With $150 Million PIPE To ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 August 2026 · Fusion42 review
Werewolf Therapeutics and Ambros Therapeutics have merged in an all-stock deal with a $150 million private placement to fund the Phase III development and planned FDA submission of neridronate, an orphan drug candidate for Complex Regional Pain Syndrome Type 1 (CRPS-1). The combined company, Ambros Therapeutics, headquartered in San Diego, aims to leverage FDA designations and orphan-drug protections to commercialize the drug pending positive Phase III results expected in 2028.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must factor in this biotech merger as it redirects $150 million in capital towards an orphan drug with strong FDA support, opening a clear path for commercialisation in CRPS-1. Take this as a sign that orphan drug markets backed by robust trial design and regulatory alignment are drawing significant investor interest, creating openings for complementary therapies or services.
◆ Coverage
1 source · 24 Aug 2026
◆ Related on Wire
◆ Topics